Furthermore, the absolute risk reduction of SGLT2 inhibitors for the composite outcome of hospitalization due to myocardial infarction, stroke or heart failure, and all-cause mortality was higher in patients with frailty. The gene discussed is SLC5A2; the disease is myocardial infarction.